Cell MedX Corp (OTCBB:CMXC) said that it now has the initial results data of the study of “metabolomic assays” evaluated in the Phase 1 lead clinical trial. It was performed in two diabetic enrollments in January 2015. The main idea was to evaluate the short-term metabolic effect of a treatment that was supported with e-balance technology. Excluding that, all other assays are pending.
Cell MedX expressed that assessment of early data shows sizeable changes in at least two key pathways that would correlate with progression in lipid metabolism and glucose. These data will help in further experimentation. It will be of crucial help in the Phase 1B clinical study. The assessment of the samples was done by well-known Metabolomics Innovation Centre. It has got informatics and analytic toolsets. Also, there are translational “omics” skills set that are helpful in cost-effective and accurate assessment of assays.
Cell MedX conducted the assessment procedure at “the Metabolomics Innovation Centre.” It is top Genome Canada backed Science & Technology Innovation Centre that is focused on metabolomics research. The center works on metabolomics at both the University of Victoria as well as the University of Alberta. It has $20 million in metabolomics tools and there is ongoing process investment for “omics” by Genome Alberta, Genome British Columbia and Genome Canada.
The other details
Cell MedX performed the evaluation procedure at the “Metabolomics Innovation Centre” as its technologies are supported by novel bioinformatics, gas chromatography, NMR and mass spectrometry tools to boost clinical trials, biomedical, agricultural, nutrient profiling and other environmental testing for several applications such as forensics, food and nutrition, human health and disease, anti-doping, petroleum research and textile sciences. It enables easy access to bioinformatics and advanced metabolomic systems for Genome Canada supported assignments. In last trading session, CMXC stock price declined 6.08% to close at $0.278.